Patents by Inventor xinlin Sun

xinlin Sun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210077637
    Abstract: The present disclosure provides a pH and oxygen dual-sensitive magnetic resonance imaging contrast agent and a preparation method thereof, which is a dual-modal nanoparticle contrast agent with 19F signal and CEST dual signal (19F-CEST), a CEST contrast agent that is dual-sensitive to pH and oxygen. The preparation method comprises: mixing a variety of phospholipid surfactants and cholesterol well to obtain a blend of phospholipid surfactants, which is dissolved in chloroform or a mixed solvent of chloroform and methanol, evaporated to dryness with a rotary evaporator and dried overnight in a vacuum oven at 40° C. after adding rhodamine, finally, it is dispersed in water containing glycerin by mechanical dispersion or ultrasonic vibration to obtain a lipid modifier; mixing perfluorocarbon, the lipid modifier obtained in step (1), glycerin, and water and ultrasonically mixing well with a probe, and extruding with an extruder to prepare a perfluorocarbon nanoemulsion.
    Type: Application
    Filed: September 30, 2020
    Publication date: March 18, 2021
    Inventors: Xinlin Sun, Lina Wu, Rong A, OLAGBAJU OLUWATOSIN ATINUKE, Kai Wang, Lili Yang, Lixin Cheng, Wenju Qiao, Xiaohong Sun
  • Publication number: 20210015439
    Abstract: Disclosed is a molecular imaging method for evaluating liver regeneration ability after ALPPS. The method includes steps of: 1) preparing a VX2 rabbit liver cancer model; 2) performing ALPPS for the VX2 rabbit liver cancer model; 3) synthesizing 18F-Fluoromethylcholine (18F-Methylcholine, 18F-FCH); 4) PET/CT imaging and data processing for 18F-FCH. The disclosure is the first to propose the use of 18F-FCH PET/CT to monitor the proliferative capacity of residual liver, and further indirectly reflect the increased ability of cell membrane synthesis on the basis that 18F-FCH has higher choline metabolism in residual liver tissue, so that the liver regeneration ability after ALPPS is evaluated by the molecular imaging method, thereby providing important new ideas for the clinical selection of ALPPS to choose the best time for second-stage surgery.
    Type: Application
    Filed: September 30, 2020
    Publication date: January 21, 2021
    Inventors: xinlin Sun, zhen Quan, Ruifeng Wang, kai Wang, lili Yang, zunyu Xiao, yang Liu, zhaoguo Han, xiang Liu, mingxing Ke